{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T09:12:01Z","timestamp":1780477921079,"version":"3.54.1"},"reference-count":35,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100010803","name":"Department of Biotechnology","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100010803","id-type":"DOI","asserted-by":"crossref"}]},{"name":"National Institute of Pharmaceutical Education and Research"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.bmcl.2020.127037","type":"journal-article","created":{"date-parts":[[2020,2,14]],"date-time":"2020-02-14T11:35:52Z","timestamp":1581680152000},"page":"127037","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Synthesis and efficacy of pyrvinium-inspired analogs against tuberculosis and malaria pathogens"],"prefix":"10.1016","volume":"30","author":[{"given":"Vikas R.","family":"Gaikwad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uttam B.","family":"Karale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gokulapriya","family":"Govindarajalu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Navin","family":"Adhikari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. Vamshi","family":"Krishna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vagolu Siva","family":"Krishna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil","family":"Misra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dharmarajan","family":"Sriram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Puran Sigh","family":"Sijwali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3958-1802","authenticated-orcid":false,"given":"Haridas B.","family":"Rode","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmcl.2020.127037_b0005","unstructured":"World Health Organization (WHO). (Report 2018), https:\/\/www.who.int\/malaria\/publications\/world-malaria-report-2018\/en\/."},{"key":"10.1016\/j.bmcl.2020.127037_b0010","unstructured":"World Health Organization (WHO). (Report 2018), https:\/\/www.who.int\/tb\/publications\/global_report\/en\/."},{"key":"10.1016\/j.bmcl.2020.127037_b0015","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1128\/AAC.05326-11","article-title":"MK-4815, a potential new oral agent for treatment of malaria","volume":"56","author":"Powles","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmcl.2020.127037_b0020","first-page":"e00012","article-title":"UCT943, a Next-generation Plasmodium falciparum PI4K inhibitor preclinical candidate for the treatment of malaria","volume":"27","author":"Brunschwig","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmcl.2020.127037_b0025","doi-asserted-by":"crossref","first-page":"5555","DOI":"10.1128\/AAC.01183-15","article-title":"ELQ-300 prodrugs for enhanced delivery and single-dose cure of malaria","volume":"59","author":"Miley","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmcl.2020.127037_b0030","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S1473-3099(15)00320-5","article-title":"Antimalarial activity of artefenomel (OZ439), a novel synthetic antimalarial endoperoxide, in patients with Plasmodium falciparum and Plasmodium vivax malaria:an open-label phase 2 trial","volume":"16","author":"Phyo","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.bmcl.2020.127037_b0035","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa1315860","article-title":"Spiroindolone KAE609 for falciparum and vivax malaria","volume":"371","author":"White","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bmcl.2020.127037_b0040","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S1473-3099(18)30374-8","article-title":"DSM265: a novel drug for single-dose cure of Plasmodium falciparum malaria","volume":"18","author":"B\u00e9lard","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.bmcl.2020.127037_b0045","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1039\/C7MD00637C","article-title":"Recent updates in the discovery and development of novel antimalarial drug candidates","volume":"9","author":"Okombo","year":"2018","journal-title":"MedChemComm"},{"key":"10.1016\/j.bmcl.2020.127037_b0050","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1038\/nm.3262","article-title":"Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis","volume":"19","author":"Pethe","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.bmcl.2020.127037_b0055","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1016\/j.bmc.2019.02.026","article-title":"3,5-Dialkoxypyridine analogues of bedaquiline are potent antituberculosis agents with minimal inhibition of the hERG channel","volume":"27","author":"Sutherland","year":"2019","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmcl.2020.127037_b0060","unstructured":"TB Alliance, Institute of Materia Medica. Phase 1a began January 16, 2019. Placebo-Controlled, Randomized, SAD Study to Evaluate the Safety, Tolerability, and PK of TBI-223 in Healthy NCT03758612. https:\/\/www.newtbdrugs.org\/pipeline\/compound\/tbi-223. Accessed on 27th September 2019."},{"key":"10.1016\/j.bmcl.2020.127037_b0065","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1056\/NEJMp1314385","article-title":"FDA approval of bedaquiline-the benefit-risk balance for drug-resistant tuberculosis","volume":"371","author":"Cox","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bmcl.2020.127037_b0070","unstructured":"https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-drug-treatment-resistant-forms-tuberculosis-affects-lungs. Accessed on 30th September 2019."},{"key":"10.1016\/j.bmcl.2020.127037_b0075","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S0022-3476(62)80042-0","article-title":"Pyrvinium pamoate in the treatment of pinworm infection (enterobiasis) in the home","volume":"60","author":"Turner","year":"1962","journal-title":"J Pediatr"},{"key":"10.1016\/j.bmcl.2020.127037_b0080","doi-asserted-by":"crossref","first-page":"349","DOI":"10.4269\/ajtmh.1959.8.349","article-title":"The treatment of pinworm infections in humans (enterobiasis) with pyrvinium chloride and pyrvinium pamoate","volume":"8","author":"Beck","year":"1959","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.bmcl.2020.127037_b0085","doi-asserted-by":"crossref","first-page":"100","DOI":"10.3347\/kjp.1977.15.2.100","article-title":"Evaluation of anthelmintic treatment of Enterobius vermicularis infection in highly endemic population by prolonged observation","volume":"15","author":"Cho","year":"1977","journal-title":"Korean J Parasitol"},{"key":"10.1016\/j.bmcl.2020.127037_b0090","first-page":"60","article-title":"Pinworm infestation in children: the problem and its treatment","volume":"86","author":"Royer","year":"1962","journal-title":"Can Med Assoc J"},{"key":"10.1016\/j.bmcl.2020.127037_b0095","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1136\/bmj.2.5319.1583","article-title":"Single-dose treatment of oxyuriasis with pyrvinium embonate","volume":"2","author":"Desai","year":"1962","journal-title":"Br Med J"},{"key":"10.1016\/j.bmcl.2020.127037_b0100","first-page":"125","article-title":"Single-dose treatment of oxyuriasis with pyrvinium pamoate (Vanquin)","volume":"10","author":"Sudigbia","year":"1970","journal-title":"Paediatr Indones"},{"key":"10.1016\/j.bmcl.2020.127037_b0105","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.tube.2009.07.002","article-title":"New anti-tuberculosis agents amongst known drugs","volume":"89","author":"Lougheed","year":"2009","journal-title":"Tuberculosis"},{"key":"10.1016\/j.bmcl.2020.127037_b0110","doi-asserted-by":"crossref","first-page":"5663","DOI":"10.1128\/AAC.00377-16","article-title":"Screening a commercial library of pharmacologically active small molecules against Staphylococcus aureus biofilms","volume":"60","author":"Torres","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmcl.2020.127037_b0115","doi-asserted-by":"crossref","first-page":"3681","DOI":"10.1128\/AAC.00680-13","article-title":"High-throughput screening of a collection of known pharmacologically active small compounds for identification of Candida albicans biofilm inhibitors","volume":"57","author":"Siles","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmcl.2020.127037_b0120","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1111\/j.1349-7006.2004.tb03330.x","article-title":"Antitumor activity of pyrvinium pamoate, 6-(dimethylamino)-2-[2-(2,5-dimethyl-1-phenyl-1H-pyrrol-3-yl)ethenyl]-1-methyl-quinolinium pamoate salt, showing preferential cytotoxicity during glucose starvation","volume":"95","author":"Esumi","year":"2004","journal-title":"Cancer Sci"},{"key":"10.1016\/j.bmcl.2020.127037_b0125","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1093\/jac\/dkp296","article-title":"In vitro activity of pyrvinium pamoate against Entamoeba histolytica and Giardia intestinalis using radiolabelled thymidine incorporation and an SYBR Green I-based fluorescence assay","volume":"64","author":"Downey","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.bmcl.2020.127037_b0130","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nchembio806","article-title":"A clinical drug library screen identifies astemizole as an antimalarial agent","volume":"2","author":"Chong","year":"2006","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.bmcl.2020.127037_b0135","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.ejmech.2019.01.002","article-title":"Synthesis and evaluation of \u03b1-aminoacyl amides as antitubercular agents effective on drug resistant tuberculosis","volume":"164","author":"Makane","year":"2019","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmcl.2020.127037_b0140","first-page":"499","article-title":"Novel 1,3,4-oxadiazoles as antitubercular agents with limited activity against drug-resistant tuberculosis. Fut","volume":"11","author":"Makane","year":"2019","journal-title":"Med Chem"},{"key":"10.1016\/j.bmcl.2020.127037_b0145","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0144018","article-title":"Identification of new molecular entities (NMEs) as potential leads against tuberculosis from open source compound repository","volume":"10","author":"Kotapalli","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1016\/j.bmcl.2020.127037_b0150","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1002\/slct.201601821","article-title":"A facile synthesis and antituberculosis properties of almazole D and its enantiomer","volume":"2","author":"Lade","year":"2017","journal-title":"ChemistrySelect"},{"key":"10.1016\/j.bmcl.2020.127037_b0155","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.ejmech.2019.05.082","article-title":"Synthesis and biological evaluation of 2,4,5-trisubstituted thiazoles as antituberculosis agents effective against drug-resistant tuberculosis","volume":"178","author":"Karale","year":"2019","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmcl.2020.127037_b0160","doi-asserted-by":"crossref","first-page":"5428","DOI":"10.1039\/C9OB00817A","article-title":"Strategies towards the synthesis of anti-tuberculosis drugs","volume":"17","author":"Rode","year":"2019","journal-title":"Org Biomol Chem"},{"key":"10.1016\/j.bmcl.2020.127037_b0165","unstructured":"Macdonald JE, Hysell MK, Yu D, Li H, Wong-Staal F. Novel quinolinium salts and derivatives. WO2006\/078754 A1; 2006."},{"key":"10.1016\/j.bmcl.2020.127037_b0170","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.3987\/COM-12-12446","article-title":"New synthesis of pyrvinium that inhibits the \u03b2-catenin\/Tcf4 pathway","volume":"85","author":"Mao","year":"2012","journal-title":"Heterocycles"},{"key":"10.1016\/j.bmcl.2020.127037_b0175","doi-asserted-by":"crossref","first-page":"6200","DOI":"10.1021\/jm400656s","article-title":"Novel conjugated quinoline-indoles compromise Plasmodium falciparum mitochondrial function and show promising antimalarial activity","volume":"56","author":"Teguh","year":"2013","journal-title":"J Med Chem"}],"container-title":["Bioorganic & Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X20301098?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X20301098?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T07:34:08Z","timestamp":1760772848000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X20301098"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":35,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["S0960894X20301098"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2020.127037","relation":{},"ISSN":["0960-894X"],"issn-type":[{"value":"0960-894X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Synthesis and efficacy of pyrvinium-inspired analogs against tuberculosis and malaria pathogens","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2020.127037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"127037"}}